Thomas Decker was involved in the pioneering studies that led to the identification of Jak-Stat signal transduction. His lab focuses on the interplay between inflammatory and/or microbe-responsive signalling pathways and Jak-Stat signal transduction.
Robert Kralovics major achievement so far has been the identification of a gain-of-function mutation in the JAK2 kinase gene (V617F) that plays an important role in myeloproliferative disorder (MPD) pathogenesis. His main research interests focus on the identification of mutations in early steps of disease development and in the cause of familial predisposition to hematological malignancies and the translation of the genetic data into predictive diagostics and therapy.
Richard Moriggl is a young investigator involved in pioneering work to define cytokine receptor and Jak-Stat gene functions. His lab focuses on the role of persistently activated Stat3 or Stat5 proteins in leukaemogenesis.
Mathias Müller participated in the pioneering studies that led to the identification of the biological roles of Jaks and Stats by genetic complementation of cytokine signalling defective mutant cell lines. His lab took part in the initial characterisation of Jak2-null mice and subsequently generated Tyk2-deficient mice.
Veronika Sexl specialises on the role of Stats, Jaks and connected pathways in mouse leukaemia models. The lab addresses the role of Stat5 in Bcr/Abl- induced leukaemia and the role of MHC-class I antigens and NK/NKT cells in immuno-surveillance of experimental leukaemias induced by the Abelson virus.
Birgit Strobl has a profound education in antiviral host responses and a long-standing expertise on Jak and Stat activities leading to antimicrobial immunity. Her group studies the canonical as well as the non-canonical mechanisms of signaling via Tyk2 and Stat1 in innate and adaptive immunity and in tumor surveillance.
Former Research Groups
Hartmut Beug was a leading expert in the areas of leukaemic renewal and carcinoma progression. He specialised on cell culture models closely mimicking tumourigenesis in vivo.
Robert Eferl is a young investigator focusing on the molecular basis of cancer, bone and lung diseases. He generates transgenic mouse models to define key factors in hepatocellular carcinoma formation and in low bone mass diseases.
Pavel Kovarik has extensively investigated the connection between Stat and inflammatory signalling. His focus is on the co-operation of Stat1 with stress kinases during signal transduction and gene transcription.
Wolfgang Mikulits focuses on tumour progression in liver cancer. His group developed novel, combined in vitro / in vivo cellular models such as immortalised hepatocytes from p19ARF–/– mice, which are fully functional in vivo.
Ernst W. Müllner focuses on the analysis of primary hematopoietic cell development and maturation, with a particular emphasis on cells of the erythroid lineage. His lab has developed novel cell culture models for chicken, mouse and human erythroblasts.